Peptide Monograph

Hexarelin

Examorelin

At a Glance

Mechanism of Action

Hexarelin (also known as examorelin) is a synthetic hexapeptide and a member of the growth hormone-releasing peptide (GHRP) family. It binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), the ghrelin receptor, on anterior pituitary somatotroph cells, activating the PLC/IP3/calcium signaling pathway to stimulate growth hormone release. Hexarelin is recognized as the most potent of the GHRP family for acute GH release, producing larger GH peaks than GHRP-6, GHRP-2, or ipamorelin at equivalent doses.[1]

A unique and distinguishing feature of hexarelin's pharmacology is its binding to the CD36 receptor (scavenger receptor class B, member 3), a multiligand receptor expressed on macrophages, cardiomyocytes, endothelial cells, and adipocytes. This CD36 interaction is independent of GH release and the GHS-R1a pathway. Broglio et al. demonstrated that hexarelin exerts cardioprotective effects via CD36 activation, including protection against ischemia-reperfusion injury, anti-atherosclerotic activity through modified lipoprotein clearance, and activation of the MAPK (mitogen-activated protein kinase) pathway in cardiac tissue. These cardiac effects persist even when GH release is blocked by somatostatin, confirming a GH-independent mechanism.[2][3]

Like other GHRPs, hexarelin also stimulates cortisol, prolactin, and ACTH release. Among the GHRP family, hexarelin produces the highest cortisol and prolactin elevations, reflecting the lowest selectivity of the group. This limits its utility for chronic GH stimulation relative to more selective agents like ipamorelin.[1][4]

A critical pharmacological characteristic of hexarelin is tachyphylaxis (desensitization) with chronic administration. The GH response to hexarelin progressively diminishes with daily use, typically becoming significantly attenuated within 4–8 weeks of continuous administration. This desensitization is thought to involve downregulation of GHS-R1a and/or alterations in postreceptor signaling. Notably, the CD36-mediated cardiac effects do not appear to undergo the same degree of desensitization, which has shifted research interest toward hexarelin's cardiac rather than endocrine applications.[1][5]

Evidence Summary

GH Release — Acute Potency

Ghigo et al. conducted extensive characterization of hexarelin's GH-releasing properties in healthy volunteers and patients with various endocrine disorders. Hexarelin consistently produced the largest acute GH peaks among the GHRP family. In head-to-head comparisons, hexarelin at 1–2 mcg/kg IV produced GH peaks of 40–80 ng/mL in healthy young adults, exceeding GHRP-6 and GHRP-2 at equivalent doses. The GH response is synergistic when combined with GHRH.[1][4]

Tachyphylaxis

A phase 2 study evaluating chronic hexarelin administration for GH deficiency demonstrated significant attenuation of the GH response within weeks of continuous daily dosing. By 4–8 weeks, the GH peak in response to hexarelin was reduced by 50% or more compared to the initial response. This tachyphylaxis was a major factor in the decision not to pursue hexarelin as a chronic therapeutic for GH deficiency or body composition improvement.[1]

Cardioprotective Effects

Broglio et al. demonstrated that hexarelin's binding to CD36 on cardiomyocytes activates protective signaling cascades including the MAPK/ERK pathway, leading to reduced apoptosis in ischemia-reperfusion models. In animal models, hexarelin reduced infarct size and improved post-ischemic cardiac function. These cardioprotective effects were maintained even when GH release was blocked with somatostatin, confirming a GH-independent mechanism.[2]

Nagaya et al. studied hexarelin in a small clinical trial of patients with severe heart failure and reported improvements in cardiac output, left ventricular ejection fraction, and exercise tolerance. While preliminary, these findings suggested that hexarelin's cardiac benefits might be clinically meaningful and independent of its GH-releasing properties.[5]

Anti-Atherosclerotic Properties

Through CD36-mediated clearance of oxidized LDL and modified lipoproteins by macrophages, hexarelin has demonstrated anti-atherosclerotic effects in animal models. Muccioli et al. characterized the molecular mechanisms of hexarelin's CD36 interaction and proposed that the scavenger receptor pathway represents a distinct therapeutic target, separable from the GH-releasing actions of GHS-R1a agonists.[3]

Primary Uses (in Research)

Based on the available literature, hexarelin has been investigated for the following applications:

• Acute GH release — Most potent GHRP for single-dose GH stimulation. Limited by tachyphylaxis for chronic use.[1]
• GH deficiency assessment — Used as a provocative agent in GH stimulation testing, though not standardized for clinical diagnostic use.[4]
• Cardioprotection — Investigation of CD36-mediated cardiac protection in ischemia-reperfusion injury, heart failure, and atherosclerosis. This represents the most active area of current hexarelin research.[2][5]
• Anti-atherosclerosis — CD36-mediated clearance of oxidized LDL in preclinical models of atherosclerosis.[3]

Contraindications

Standard Protocols

Tachyphylaxis management: Due to the well-documented desensitization of GH response with chronic hexarelin use, some research protocols employ intermittent dosing (5 days on / 2 days off, or alternating weeks) in an attempt to preserve GH responsiveness. The efficacy of these cycling strategies has not been rigorously evaluated.[1]

As with other GH secretagogues, hexarelin is typically administered on an empty stomach (fasting for at least 30 minutes before and after) to maximize GH pulse amplitude.

Common Stacks & Synergies

In the peptide research community, hexarelin is less commonly stacked than GHRP-2 or ipamorelin, partly due to its tachyphylaxis issues and higher side effect burden. The following combinations are sometimes discussed:

• Hexarelin + GHRH analog (CJC-1295 or Mod GRF 1-29) — Synergistic GH release via complementary PLC/IP3 and cAMP pathways. Produces the largest acute GH pulses of any GHRP/GHRH combination. Limited by hexarelin's tachyphylaxis for chronic protocols.
• Hexarelin as a "pulse" agent — Some protocols use hexarelin intermittently (e.g., once weekly) for large acute GH pulses while using a more selective daily GH secretagogue (ipamorelin) for baseline GH support. No clinical data supports this approach.
• Hexarelin for cardiac applications — When investigated for cardioprotective purposes, hexarelin has been studied as a standalone agent, as the cardiac effects via CD36 do not require GH release synergy.[2]

Preparation & Administration

Hexarelin is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 2 mg, 5 mg, or 10 mg of peptide. It must be reconstituted with bacteriostatic water (BAC water) before injection.

Reconstitution

For a standard 5 mg vial reconstituted with 2.5 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 200 mcg. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. Common injection sites include the abdominal subcutaneous tissue (periumbilical area). Rotate injection sites to avoid lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Intranasal

Intranasal hexarelin has been explored in limited research settings. Bioavailability is lower than subcutaneous administration and is not well-characterized. This route is not commonly used.

Side Effects & Adverse Events

Commonly reported side effects:

• Hunger increase: Appetite stimulation via ghrelin receptor agonism. Less intense than GHRP-6 but more pronounced than ipamorelin.
• Water retention: Moderate fluid retention, potentially manifesting as puffy appearance, swollen extremities, or weight gain.
• Cortisol elevation: The highest cortisol stimulation of the GHRP family. Chronic elevation may contribute to insulin resistance, immune suppression, and other hypercortisolism-related effects.[1][4]
• Prolactin elevation: The most pronounced prolactin increase among GHRPs. May lead to gynecomastia, galactorrhea, or reproductive disturbances with chronic use at higher doses.[4]
• Flushing: Skin flushing and warmth, more commonly reported with hexarelin than other GHRPs.
• Tachyphylaxis: Progressive loss of GH response with daily use, typically significant by 4–8 weeks. This is a pharmacological effect rather than an adverse event, but it is clinically relevant as it limits therapeutic utility.[1]
• Numbness and tingling: Transient paresthesias in hands and feet related to acute GH release.
• Joint pain: Arthralgia associated with GH-mediated fluid retention.
• Injection site reactions: Redness, swelling, or mild pain at the injection site.

Drug Interactions

No formal drug interaction studies have been conducted with hexarelin in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:

• Insulin and oral hypoglycemics — GH elevates blood glucose via insulin resistance. Diabetic patients using insulin or sulfonylureas may require dose adjustments.
• Corticosteroids — Hexarelin produces the highest cortisol elevation of the GHRP family. Concurrent exogenous corticosteroid use may significantly amplify hypercortisolism-related adverse effects.
• Somatostatin analogs (octreotide, lanreotide) — Will block hexarelin's GH-releasing effects via GHS-R1a. Notably, hexarelin's CD36-mediated cardiac effects are preserved during somatostatin co-administration.[2]
• Antiarrhythmic agents — Hexarelin's direct cardiac activity via CD36 warrants caution with concurrent antiarrhythmic drugs. The interaction profile is not characterized.
• Dopamine agonists (cabergoline, bromocriptine) — These agents suppress prolactin and may be used to manage hexarelin-induced prolactin elevation. No formal interaction data exists.

Storage & Handling

Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.

Legal & Regulatory Status

• FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Sold under the research chemical designation "not for human consumption."
• WADA (World Anti-Doping Agency) — Prohibited at all times under class S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes subject to anti-doping testing should not use hexarelin.
• European Union — Not approved as a medicinal product. Available as a research chemical. Phase 2 studies were conducted in Italy but did not advance to approval.
• Australia (TGA) — Not approved. Classified as a Schedule 4 prescription-only substance under the Poisons Standard.

Open Questions

Key unresolved questions regarding hexarelin include:

• Cardiac applications — Whether hexarelin's CD36-mediated cardioprotective effects can be translated into clinical therapies for heart failure, ischemic heart disease, or atherosclerosis. The dissociation between cardiac and GH effects makes this a compelling but underdeveloped therapeutic avenue.[2][5]
• Tachyphylaxis management — Whether intermittent dosing, cycling strategies, or combination with other agents can mitigate GH response desensitization while preserving hexarelin's benefits.
• CD36 mechanism clinical relevance — The precise clinical significance of CD36-mediated effects in humans is not established. Whether hexarelin-like CD36 agonists could become a new drug class for cardiovascular disease is an open question.[3]
• Selective CD36 agonists — Whether compounds can be designed that activate CD36 without GHS-R1a, thereby preserving cardiac benefits while eliminating GH-related side effects and tachyphylaxis.
• Long-term safety — The consequences of chronic hexarelin use, particularly regarding cortisol/prolactin elevation and cardiac effects, are not characterized beyond short-term phase 2 data.

Bibliography

1. Ghigo E, Arvat E, Muccioli G, Camanni F. "Growth hormone-releasing peptides." Eur J Endocrinol. 1997;136(5):445-460. doi:10.1530/eje.0.1360445. PMID:9186261.
2. Broglio F, Benso A, Gottero C, Prodam F, Gauna C, Filtri L, Arvat E, van der Lely AJ, Deghenghi R, Ghigo E. "Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans." J Endocrinol Invest. 2003;26(3):192-196. doi:10.1007/BF03345156. PMID:12809168.
3. Muccioli G, Pons N, Ghe C, Catapano F, Granata R, Ghigo E. "Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor." Eur J Pharmacol. 2004;498(1-3):27-35. doi:10.1016/j.ejphar.2004.07.066. PMID:15363972.
4. Arvat E, Maccagno B, Ramunni J, Broglio F, Deghenghi R, Camanni F, Ghigo E. "Effects of hexarelin, a synthetic GH-releasing peptide, on GH, prolactin and cortisol release in man." Neuroendocrinology. 1995;61:584-589. PMID:7659751.
5. Nagaya N, Kangawa K. "Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia." Intern Med. 2006;45(3):127-134. doi:10.2169/internalmedicine.45.1596. PMID:16508225.